Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways

Yozo Mitsui; Hiroshi Hirata; Naoko Arichi; Miho Hiraki; Hiroaki Yasumoto; Inik Chang; Shinichiro Fukuhara; Soichiro Yamamura; Varahram Shahryari; Guoren Deng; Sharanjot Saini; Shahana Majid; Rajvir Dahiya; Yuichiro Tanaka; Hiroaki Shiina

doi:10.18632/oncotarget.3445

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways

Yozo Mitsui _, Hiroshi Hirata, Naoko Arichi, Miho Hiraki, Hiroaki Yasumoto, Inik Chang, Shinichiro Fukuhara, Soichiro Yamamura, Varahram Shahryari, Guoren Deng, Sharanjot Saini, Shahana Majid, Rajvir Dahiya, Yuichiro Tanaka and Hiroaki Shiina

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:9577-9591. https://doi.org/10.18632/oncotarget.3445

Metrics: PDF 2199 views | HTML 2602 views | ?

Abstract

Yozo Mitsui1,2, Hiroshi Hirata2, Naoko Arichi1, Miho Hiraki1, Hiroaki Yasumoto1, Inik Chang3, Shinichiro Fukuhara4, Soichiro Yamamura2, Varahram Shahryari2, Guoren Deng2, Sharanjot Saini2, Shahana Majid2, Rajvir Dahiya2, Yuichiro Tanaka2 and Hiroaki Shiina1

1 Department of Urology, Shimane University Faculty of Medicine, Enya-cho, Izumo, Japan

2 Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, USA

3 Department of Oral Biology, Yonsei University College of Densitry, Seoul, South Korea

4 Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan

Correspondence to:

Yozo Mitsui, email:

Keywords: bone morphogenetic protein 2, renal cell carcinoma, DNA methylation, molecular marker

Received: January 15, 2015 Accepted: February 10, 2015 Published: March 07, 2015

Abstract

We investigated whether impaired regulation of bone morphogenetic protein-2 (BMP-2) via epigenetic pathways is associated with renal cell carcinoma (RCC) pathogenesis. Expression and CpG methylation of the BMP-2 gene were analyzed using RCC cell lines, and 96 matched RCC and normal renal tissues. We also performed functional analysis using BMP-2 restored RCC cells. A significant association of BMP-2 mRNA expression was also found with advanced tumor stage and lymph node involvement, while lower BMP-2 mRNA expression was significantly associated with poor overall survival after radical nephrectomy. In RCC cells, BMP-2 restoration significantly inhibited cell proliferation, migration, invasion, and colony formation. In addition, BMP-2 overexpression induced p21WAF1/CIP1 and p27KIP1 expression, and cellular apoptosis in RCC cells. BMP-2 mRNA expression was significantly enhanced in RCC cells by 5-aza-2’-deoxycitidine treatment. The prevalence of BMP-2 promoter methylation was significantly greater and BMP-2 mRNA expression was significantly lower in RCC samples as compared to normal kidney samples. Furthermore, a significant correlation was found between BMP-2 promoter methylation and mRNA transcription in tumors. Aberrant BMP-2 methylation and the resultant loss of BMP-2 expression may be a useful molecular marker for designing improved diagnostic and therapeutic strategies for RCC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3445

Publication Alerts

Clinical Research Papers:

Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways

Abstract